Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL

Ibrutinib has generated remarkable responses in patients with chronic lymphocytic leukemia (CLL), including those with an unfavorable cytogenetic profile. However, patients develop resistance, with poor outcomes and no established treatment options. Mutations in BTK and PLCG2 have emerged as main me...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Kadri, Sabah, Lee, Jimmy, Fitzpatrick, Carrie, Galanina, Natalie, Sukhanova, Madina, Venkataraman, Girish, Sharma, Shruti, Long, Brad, Petras, Kristin, Theissen, Megan, Ming, Mei, Kobzev, Yuri, Kang, Wenjun, Guo, Ailin, Wang, Weige, Niu, Nifang, Weiner, Howard, Thirman, Michael, Stock, Wendy, Smith, Sonali M., Nabhan, Chadi, Segal, Jeremy P., Lu, Pin, Wang, Y. Lynn
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728051/
https://ncbi.nlm.nih.gov/pubmed/29296715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016003632
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars